FR19C1031I2 - Modification du facteur fviii en fonction du site - Google Patents

Modification du facteur fviii en fonction du site

Info

Publication number
FR19C1031I2
FR19C1031I2 FR19C1031C FR19C1031C FR19C1031I2 FR 19C1031 I2 FR19C1031 I2 FR 19C1031I2 FR 19C1031 C FR19C1031 C FR 19C1031C FR 19C1031 C FR19C1031 C FR 19C1031C FR 19C1031 I2 FR19C1031 I2 FR 19C1031I2
Authority
FR
France
Prior art keywords
site
modification
factor depending
fviii factor
fviii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR19C1031C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Healthcare LLC
Original Assignee
Bayer Healthcare LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36337298&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR19C1031(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare LLC filed Critical Bayer Healthcare LLC
Publication of FR19C1031I1 publication Critical patent/FR19C1031I1/fr
Application granted granted Critical
Publication of FR19C1031I2 publication Critical patent/FR19C1031I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
FR19C1031C 2004-11-12 2019-05-07 Modification du facteur fviii en fonction du site Active FR19C1031I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62727704P 2004-11-12 2004-11-12
PCT/US2005/041205 WO2006053299A2 (fr) 2004-11-12 2005-11-14 Modification du facteur fviii en fonction du site

Publications (2)

Publication Number Publication Date
FR19C1031I1 FR19C1031I1 (fr) 2019-06-28
FR19C1031I2 true FR19C1031I2 (fr) 2020-06-05

Family

ID=36337298

Family Applications (1)

Application Number Title Priority Date Filing Date
FR19C1031C Active FR19C1031I2 (fr) 2004-11-12 2019-05-07 Modification du facteur fviii en fonction du site

Country Status (32)

Country Link
US (4) US7632921B2 (fr)
EP (9) EP2772500B1 (fr)
JP (5) JP2008524117A (fr)
KR (7) KR20180110192A (fr)
CN (6) CN103102406B (fr)
AU (1) AU2005304622B2 (fr)
BR (2) BR122016022033B8 (fr)
CA (1) CA2586379C (fr)
CY (3) CY1119292T1 (fr)
DK (3) DK2363414T3 (fr)
ES (4) ES2633916T3 (fr)
FR (1) FR19C1031I2 (fr)
HK (3) HK1117875A1 (fr)
HN (1) HN2007015683A (fr)
HR (2) HRP20180481B1 (fr)
HU (5) HUE033776T2 (fr)
IL (3) IL182903A (fr)
LT (5) LT2371856T (fr)
LU (1) LUC00118I2 (fr)
MA (1) MA29663B1 (fr)
MX (2) MX2007005466A (fr)
NL (1) NL300989I2 (fr)
NO (3) NO20210454A1 (fr)
NZ (1) NZ555032A (fr)
PH (2) PH12014500352A1 (fr)
PL (3) PL1824988T3 (fr)
PT (4) PT1824988T (fr)
RU (1) RU2423380C2 (fr)
SI (4) SI2363414T1 (fr)
UA (1) UA95225C2 (fr)
WO (1) WO2006053299A2 (fr)
ZA (1) ZA200703696B (fr)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2338333B1 (fr) 2003-04-09 2017-09-06 ratiopharm GmbH Méthode de glycopegylation et proteines/peptides produits au moyen de ces méthodes
WO2005012484A2 (fr) 2003-07-25 2005-02-10 Neose Technologies, Inc. Conjugues anticorps-toxines
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
WO2006005058A2 (fr) 2004-06-30 2006-01-12 Nektar Therapeutics Al, Corporation Conjugues polymere-fraction facteur ix
WO2006010143A2 (fr) 2004-07-13 2006-01-26 Neose Technologies, Inc. Remodelage de peg ramifie et glycosylation de peptide-1 semblable a glucagon [glp-1]
SI2586456T1 (sl) 2004-10-29 2016-05-31 Ratiopharm Gmbh Preoblikovanje in glikopegliacija fibroblastnega rastnega faktorja (FGF)
WO2006053299A2 (fr) 2004-11-12 2006-05-18 Bayer Healthcare Llc Modification du facteur fviii en fonction du site
EP1858543B1 (fr) 2005-01-10 2013-11-27 BioGeneriX AG Facteur de stimulation de colonie de granulocytes glycopegylé
WO2006121569A2 (fr) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions et methodes utilisees pour la preparation de mutants par glycosylation de l'hormone de croissance humaine resistant a la protease
EP2360170A3 (fr) 2005-06-17 2012-03-28 Novo Nordisk Health Care AG Réduction et dérivatisation de protéines obtenues par génie génétique comprenant au moins une cystéine non native
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
US20090252720A1 (en) * 2006-05-24 2009-10-08 Novo Nordisk Health Care Ag Prolonged FIX Analogues and Derivatives
CN101516388B (zh) 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
EP2054521A4 (fr) 2006-10-03 2012-12-19 Novo Nordisk As Méthodes de purification de conjugués de polypeptides
DK2101821T3 (da) 2006-12-15 2014-10-06 Baxter Healthcare Sa Faktor VIIA-(poly)sialinsyre-konjugat med forlænget halveringstid in vivo
ES2406267T3 (es) 2007-04-03 2013-06-06 Biogenerix Ag Métodos de tratamiento usando G-CSF glicopegilado
WO2008154639A2 (fr) 2007-06-12 2008-12-18 Neose Technologies, Inc. Procédé amélioré pour la production de sucres de nucléotide
KR20100095441A (ko) * 2007-11-09 2010-08-30 백스터 인터내셔널 인코포레이티드 변형된 재조합 인자 ⅷ 및 폰 빌레브란트 인자 및 사용 방법
PL2257311T3 (pl) * 2008-02-27 2014-09-30 Novo Nordisk As Koniugaty cząsteczek czynnika VIII
CN102112144A (zh) 2008-05-16 2011-06-29 拜耳医药保健有限公司 靶向性凝固因子及其使用方法
KR20110017420A (ko) * 2008-06-04 2011-02-21 바이엘 헬스케어 엘엘씨 폰 빌레브란트 질환의 치료를 위한 ｆｖｉｉｉ 뮤테인
KR101648734B1 (ko) 2008-06-24 2016-08-18 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 인자 ｖｉｉｉ, 폰 빌레브란트 인자 또는 이들의 복합체
WO2010019263A2 (fr) * 2008-08-15 2010-02-18 Genzyme Corporation Produits de construction de flt soluble pour traiter des cancers
KR20110071012A (ko) * 2008-10-17 2011-06-27 백스터 인터내셔널 인코포레이티드 낮은 수준의 수용성 중합체를 포함하는 개질된 혈액 인자
EP2352515A4 (fr) * 2008-11-03 2012-04-25 Bayer Healthcare Llc Procédé de traitement de l'hémophilie
JP2012510060A (ja) * 2008-11-24 2012-04-26 バイエル・ヘルスケア・エルエルシー シリカをベースとする活性化部分トロンボプラスチン時間アッセイにおけるｐｅｇ化血液凝固因子の活性の測定方法
EP2387413A4 (fr) * 2009-01-19 2015-12-23 Bayer Healthcare Llc Conjugué protéique ayant une fraction bio-protectrice pouvant être clivée par une endopeptidase
MX362028B (es) 2009-02-03 2019-01-04 Amunix Pharmaceuticals Inc Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
CN102333788A (zh) * 2009-02-19 2012-01-25 诺沃—诺迪斯克有限公司 因子viii的修饰
EP2408800B1 (fr) * 2009-03-20 2016-05-25 Hanmi Science Co., Ltd. Procédé de préparation d'un conjugué site-spécifié d'un polypeptide physiologiquement actif
CN102427823A (zh) * 2009-03-24 2012-04-25 拜耳医药保健有限公司 因子viii变体及使用方法
JP5908401B2 (ja) 2009-07-27 2016-04-26 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 血液凝固タンパク質複合体
HUE028056T2 (en) 2009-07-27 2016-11-28 Baxalta GmbH Blood coagulation protein conjugates
WO2011012850A2 (fr) 2009-07-27 2011-02-03 Lipoxen Technologies Limited Glyco-polysialylation de protéines de coagulation non sanguine
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
AU2010290077C1 (en) * 2009-08-24 2015-12-03 Bioverativ Therapeutics Inc. Coagulation factor IX compositions and methods of making and using same
ES2880038T3 (es) 2009-12-06 2021-11-23 Bioverativ Therapeutics Inc Polipéptidos quiméricos e híbridos de factor VIII-Fc, y métodos de uso de los mismos
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
CN102770449B (zh) 2010-02-16 2016-02-24 诺沃—诺迪斯克有限公司 具有降低的vwf结合的因子viii分子
RS59827B1 (sr) * 2010-02-21 2020-02-28 Bayer Healthcare Llc Metoda za aktiviranje i konjugovanje biomolekula
CN106432557A (zh) 2010-04-15 2017-02-22 科迪亚科学企业公司 高分子量的含两性离子的聚合物
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
GB201007357D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
WO2012006623A1 (fr) * 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Systèmes pour le traitement du facteur viii et procédés associés
EP2635297B1 (fr) * 2010-11-05 2019-02-27 Baxalta GmbH Un nouveau variant du facteur viii anti-hémophile ayant une activité spécifique accrue
JP2014501227A (ja) * 2010-12-16 2014-01-20 ノヴォ ノルディスク アー／エス 第ｖｉｉｉ因子水溶液
CA2822591C (fr) 2010-12-22 2020-12-29 Baxter International Inc. Materiels et methodes pour la conjugaison d'un derive d'acide gras soluble dans l'eau a une proteine
AU2012262428C1 (en) * 2011-05-27 2018-10-11 Takeda Pharmaceutical Company Limited Therapeutic proteins with increased half-life and methods of preparing same
PL2717898T3 (pl) 2011-06-10 2019-06-28 Bioverativ Therapeutics Inc. Związki o działaniu prokoagulacyjnym i sposoby ich stosowania
CN103930440A (zh) 2011-07-01 2014-07-16 拜耳知识产权有限责任公司 松弛素融合多肽及其用途
RS58578B1 (sr) 2011-07-08 2019-05-31 Bioverativ Therapeutics Inc Faktor viii himernih i hibridnih polipeptida i postupci za njihovu upotrebu
CA2849673A1 (fr) 2011-09-23 2013-03-28 Novo Nordisk A/S Nouveaux analogues du glucagon
KR20130049671A (ko) * 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
ES2771208T3 (es) 2012-02-15 2020-07-06 Bioverativ Therapeutics Inc Composiciones de factor VIII y métodos de preparación y uso de las mismas
EP2814502B1 (fr) 2012-02-15 2017-09-13 CSL Behring GmbH Variants du facteur de von willebrand ayant une affinité de liaison au facteur viii améliorée
EP3549953A1 (fr) 2012-02-15 2019-10-09 Bioverativ Therapeutics Inc. Protéines de facteur viii de recombinaison
EP2666782A1 (fr) 2012-05-22 2013-11-27 Imnate Sarl Facteur VIII de coagulation avec immunogénicité réduite
CA2875246A1 (fr) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Composes pro-coagulants
EP2870250B2 (fr) 2012-07-06 2022-06-29 Bioverativ Therapeutics Inc. Lignée cellulaire exprimant des polypeptides de facteur viii à une seule chaîne et ses utilisations
EP2908847B1 (fr) 2012-10-18 2022-03-30 Bioverativ Therapeutics Inc. Procédés d'utilisation d'une dose fixe d'un facteur de coagulation
WO2014070953A1 (fr) 2012-10-30 2014-05-08 Biogen Idec Ma Inc. Procédés d'utilisation du polypeptide fviii
LT2968477T (lt) 2013-03-15 2020-03-10 Bioverativ Therapeutics Inc. Faktoriaus viii polipeptido kompozicijos
US20160030524A1 (en) * 2013-03-15 2016-02-04 Bayer Healthcare Llc Recombinant factor viii formulations
AU2014228938B2 (en) 2013-03-15 2019-05-02 Bioverativ Therapeutics Inc. Factor IX polypeptide formulations
KR20160021758A (ko) 2013-04-18 2016-02-26 노보 노르디스크 에이/에스 의학용으로 사용하기 위한 안정하고 연장된 glp-1/글루카곤 수용체 코-아고니스트
EP2796145B1 (fr) 2013-04-22 2017-11-01 CSL Ltd. Un complexe covalent de facteur von willebrand et de faktor viii conjugé par un pont disulfure
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
WO2015023894A1 (fr) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Protéines de facteur viii de recombinaison
WO2015023891A2 (fr) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Fusions de facteur vii-xten et leurs utilisations
WO2015035342A2 (fr) 2013-09-08 2015-03-12 Oligasis Llc Conjugués polymère zwittérionique-facteur viii
EP3060242A1 (fr) * 2013-10-22 2016-08-31 DBV Technologies Procédé pour traiter l'hémophilie en induisant une tolérance de facteurs sanguins
EP3065769A4 (fr) 2013-11-08 2017-05-31 Biogen MA Inc. Composé de fusion procoagulant
RU2546297C1 (ru) * 2013-11-19 2015-04-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство, улучшающее реологические свойства крови
ES2967617T3 (es) 2013-12-06 2024-05-03 Bioverativ Therapeutics Inc Herramientas de farmacocinética poblacional y sus usos
RU2695428C2 (ru) * 2014-01-20 2019-07-23 Октафарма Аг СПОСОБ ПРОИЗВОДСТВА ФАКТОРА VIII, ИМЕЮЩЕГО УЛУЧШЕННОЕ СООТНОШЕНИЕ FVIII:C/FVIII:Ag
KR102382402B1 (ko) 2014-02-04 2022-04-01 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
EP3114138B1 (fr) 2014-03-05 2021-11-17 Pfizer Inc. Mutéines améliorées du facteur viii de coagulation
MX2016012447A (es) 2014-03-24 2017-01-06 Biogen Ma Inc Formulaciones de factor ix liofilizadas.
US11181534B2 (en) * 2014-04-04 2021-11-23 Bloodworks Routine laboratory and point-of-care (POC) testing for hemostasis
WO2015157335A1 (fr) 2014-04-10 2015-10-15 Bayer Healthcare Llc Formulation de poudre de milieux mélangés et procédé de préparation de milieu liquide pour la culture cellulaire
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
DK3164150T3 (da) 2014-07-02 2021-02-08 CSL Behring Lengnau AG Modificeret von willebrand-faktor
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
US11155601B2 (en) 2015-03-06 2021-10-26 CSL Behring Lengnau AG Modified von Willebrand factor having improved half-life
EP3298036B1 (fr) 2015-05-22 2022-04-06 CSL Behring Lengnau AG Procédés de préparation du facteur willebrand modifié
JP6573989B2 (ja) 2015-05-22 2019-09-11 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 血友病を処置するための切断型フォン・ヴィルブランド因子ポリペプチド
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
SG11201805497QA (en) 2016-01-07 2018-07-30 Csl Behring Recombinant Facility Ag Mutated truncated von willebrand factor
SG10201912857XA (en) 2016-01-07 2020-02-27 CSL Behring Lengnau AG Mutated von willebrand factor
CN109689683A (zh) * 2016-06-24 2019-04-26 财团法人牧岩生命科学研究所 重组单链fvⅲ及其化学缀合物
DK3538133T3 (da) 2016-11-11 2021-04-19 CSL Behring Lengnau AG Trunkeret von willebrand faktor polypeptider til behandling af hæmofili
JP2020504082A (ja) 2016-11-11 2020-02-06 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 血液凝固障害の処置又は予防における血管外投与のための切断型フォン・ヴィルブランド因子ポリペプチド
BR112019010034A2 (pt) 2016-11-16 2019-09-03 Bayer Healthcare Llc fator viii alvejado de hemácia e método de uso do mesmo
BR112019011198A2 (pt) 2016-12-02 2019-12-17 Bioverativ Therapeutics Inc métodos de indução de tolerância imune a fatores de coagulação
BR112019011115A2 (pt) 2016-12-02 2019-10-01 Bioverativ Therapeutics Inc métodos para tratar artropatia hemofílica usando fatores de coagulação quiméricos
AU2018215092A1 (en) 2017-01-31 2019-08-29 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
JP2021523878A (ja) 2018-05-18 2021-09-09 バイオベラティブ セラピューティクス インコーポレイテッド 血友病ａを処置する方法
JP2022553640A (ja) 2019-10-10 2022-12-26 コディアック サイエンシーズ インコーポレイテッド 眼障害を処置する方法
WO2021091881A1 (fr) * 2019-11-04 2021-05-14 The Trustees Of Columbia University In The City Of New York Compositions de conjugués d'inhibiteurs de caspase de pénétration cellulaire à concentration élevée et procédés associés
EP4069269A4 (fr) * 2019-12-06 2023-12-27 The Children's Hospital Of Philadelphia Compositions et procédés de modulation de la fonction du facteur viii

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59172425A (ja) * 1983-03-18 1984-09-29 Nippon Chemiphar Co Ltd 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤
US7138505B1 (en) 1984-01-12 2006-11-21 Novartis Vaccines And Diagnostics, Inc. Factor VIII:C nucleic acid molecules
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5171844A (en) 1987-06-12 1992-12-15 Gist-Brocades N.W. Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
EP0690126B1 (fr) 1987-06-12 2001-11-28 Baxter Aktiengesellschaft Protéines à activité de facteur VIII, procédé pour leur production utilisant des cellules modifiées par génie génétique et compositions pharmaceutiques les contenant
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
AU2473388A (en) * 1987-11-16 1989-06-22 Scripps Clinic And Research Foundation Treatment of factor viii inhibitors
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
DK0627924T3 (da) 1992-10-02 2001-04-30 Genetics Inst Sammensætning, der omfatter koagulationsfaktor VIII formulering, fremgangsmåde til dens fremstilling og anvendelse af et overfladeaktivt middel som stabilisator
WO1994015625A1 (fr) * 1993-01-15 1994-07-21 Enzon, Inc. Conjugues de polymere et de facteur viii
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
EP0730660A4 (fr) 1993-10-29 1998-02-25 Incyte Pharma Inc Proteines chimeres contenant des variantes de la protease nexine-1
IL113010A (en) 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
BE1008491A3 (fr) * 1994-07-14 1996-05-07 Croix Rouge De Belgique Depart Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci.
EP0788375A2 (fr) 1994-11-09 1997-08-13 Robin Ewart Offord Polymeres fonctionnalises destines a une ligation dirigee
AU691111B2 (en) * 1995-06-21 1998-05-07 Google Technology Holdings LLC Method and antenna for providing an omnidirectional pattern
WO1997003195A1 (fr) 1995-07-11 1997-01-30 Chiron Corporation Nouveaux analogues polypeptidiques de facteur viii:c ayant des sites de protease modifies
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
AT403438B (de) 1996-05-24 1998-02-25 Immuno Ag Pharmazeutische präparation mit faktor viii prokoagulationsaktivität und vwf-bindungsaktivität
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
RU2199347C2 (ru) * 1996-08-02 2003-02-27 Орто-Макнейл Фармасьютикал, Инк. Полипептиды, обладающие единственным ковалентно связанным n-концевым водорастворимым полимером
CA2225189C (fr) 1997-03-06 2010-05-25 Queen's University At Kingston Gene et proteine du facteur viii du chien et methodes d'utilisation
ATE375363T1 (de) 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
WO1999020288A1 (fr) * 1997-10-17 1999-04-29 Harvest Technologies Corporation Precipitation d'un concentre de fibrinogene enrichi d'un facteur de croissance obtenue a partir d'un plasma enrichi aux plaquettes
EP0922446A1 (fr) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Préparation des conjugués du GRF-PEG par un méthode en solution spécifique à un site
PT1079805E (pt) 1998-04-27 2005-03-31 Opperbas Holding Bv Composicao farmaceutica compreendendo factor viii e lipossomas neutros
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
DK1129186T4 (da) 1998-11-10 2017-02-06 Stichting Sanquin Bloedvoorziening Et faktor VIII-polypeptid med faktor VIII:C-aktivitet
US6136599A (en) 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
IL144259A0 (en) 1999-01-14 2002-05-23 Bolder Biotechnology Inc Methods for making proteins containing free cysteine residues
WO2000071714A2 (fr) 1999-05-24 2000-11-30 The American National Red Cross Procedes de reduction de la clairance du facteur viii et compositions correspondantes
RU2278123C2 (ru) * 2000-02-11 2006-06-20 Максиджен Холдингз Лтд. Молекулы, подобные фактору vii или viia
JP2004525608A (ja) 2000-09-19 2004-08-26 エモリー ユニバーシテイ 修飾された因子ｖｉｉｉ
JP2005518181A (ja) 2001-01-12 2005-06-23 ジ・アメリカン・ナショナル・レッド・クロス 第ｖｉｉｉ因子のヘパラン硫酸プロテオグリカン仲介性クリアランスを低下させるための方法および組成物
AU2002249096B2 (en) * 2001-03-22 2007-06-28 Novo Nordisk Health Care Ag Coagulation factor VII derivatives
WO2002098454A2 (fr) 2001-05-31 2002-12-12 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Molecules recombinees a immunogenicite reduite, procedes et produits intermediaires pour les obtenir et leur utilisation dans des compositions pharmaceutiques et des outils diagnostiques
WO2002096454A1 (fr) 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Molecules recombinees avec immunogenicite reduite, procedes et intermediaires permettant d'obtenir ces molecules, et utilisation de ces molecules dans des compositions pharmaceutiques et des outils diagnostiques
ES2331909T3 (es) 2001-06-14 2010-01-20 The Scripps Research Institute Factor viii estabilizado con enlaces disulfuro modificados geneticamente.
CA2461443C (fr) 2001-10-05 2011-07-12 Emory University Sequences d'acides nucleiques et d'acides amines codant des polypeptides de facteur viii a expresseur a haut rendement et leurs procedes d'utilisation
BR0308860A (pt) 2002-04-18 2005-01-04 Merck Patent Gmbh Fator viii modificado
JP4412461B2 (ja) 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
US8003117B2 (en) 2002-11-20 2011-08-23 Nof Corporation Polyalkylene glycol derivative and modified bio-related substance
WO2004060965A2 (fr) 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Polymeres a terminaison maleimide hydrolytiquement stables
ES2308032T5 (es) 2002-12-31 2017-04-24 Nektar Therapeutics Derivados poliméricos de ácido maleámico y sus bioconjugados
KR101207247B1 (ko) 2003-01-06 2012-12-03 넥타르 테라퓨틱스 티올-선택성 수용성 중합체 유도체
CN1767857A (zh) * 2003-02-26 2006-05-03 尼克塔治疗亚拉巴马公司 聚合物－因子ⅷ部分共轭物
US20040180054A1 (en) * 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
KR20060028675A (ko) * 2003-05-12 2006-03-31 아피맥스, 인크. 신규한 폴리 (에틸렌 글리콜) 개질 화합물 및 그의 용도
EP2644206B1 (fr) 2003-05-23 2019-04-03 Nektar Therapeutics Derives du PEG qui contiennent deux chaînes de PEG
EP1502921A1 (fr) 2003-07-29 2005-02-02 ZLB Behring GmbH Mutants du Facteur VIII (FVIII) humain recombinants ayant une meilleure stabilité
WO2005046583A2 (fr) 2003-10-30 2005-05-26 Emory University Facteur fviii modifie presentant une immunogenicite reduite par mutagenese d'epitopes a2 et c2
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
WO2005055930A2 (fr) 2003-12-03 2005-06-23 University Of Rochester Facteur viii recombine presentant une activite specifique amelioree
WO2006027111A1 (fr) 2004-09-06 2006-03-16 Zlb Behring Gmbh Facteur viii de coagulation modifie presentant une meilleure stabilite
WO2006053299A2 (fr) 2004-11-12 2006-05-18 Bayer Healthcare Llc Modification du facteur fviii en fonction du site
EP1871801A2 (fr) 2005-04-01 2008-01-02 Novo Nordisk Health Care AG Analogues du fviii de coagulation sanguine
CA2647314A1 (fr) * 2006-03-31 2007-11-08 Baxter International Inc. Facteur viii pegyle
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates

Also Published As

Publication number Publication date
KR20140019489A (ko) 2014-02-14
JP2008524117A (ja) 2008-07-10
IL232540A0 (en) 2014-06-30
ES2633916T3 (es) 2017-09-26
EP1824988B1 (fr) 2017-04-19
EP3153181A1 (fr) 2017-04-12
EP2772500B1 (fr) 2019-12-25
LT1824988T (lt) 2017-10-25
NL300989I2 (nl) 2019-11-28
KR20160105928A (ko) 2016-09-07
AU2005304622B2 (en) 2012-03-29
CN103102406B (zh) 2015-05-27
CY1119292T1 (el) 2018-02-14
HUE060016T2 (hu) 2023-01-28
LTPA2019509I1 (lt) 2019-08-26
EP1824988A4 (fr) 2008-12-31
MA29663B1 (fr) 2008-08-01
BRPI0517795A (pt) 2008-10-21
CN103214569A (zh) 2013-07-24
SI3130601T1 (sl) 2020-11-30
IL182903A (en) 2014-09-30
US7632921B2 (en) 2009-12-15
HK1117875A1 (en) 2009-01-23
DK2363414T3 (da) 2022-08-08
EP2363414A3 (fr) 2012-03-21
EP1824988A2 (fr) 2007-08-29
EP3243833B1 (fr) 2020-06-17
BRPI0517795B8 (pt) 2021-05-25
EP3323829B1 (fr) 2020-07-15
JP2015134780A (ja) 2015-07-27
EP3243834A1 (fr) 2017-11-15
LTC1824988I2 (lt) 2021-02-25
WO2006053299A2 (fr) 2006-05-18
KR20140091618A (ko) 2014-07-21
MX2007005466A (es) 2007-10-19
HN2007015683A (es) 2011-07-11
US20130274445A1 (en) 2013-10-17
JP2013067621A (ja) 2013-04-18
NO345800B1 (no) 2021-08-09
LT3130601T (lt) 2020-09-10
NZ555032A (en) 2010-02-26
BRPI0517795A8 (pt) 2018-12-26
CN103102406A (zh) 2013-05-15
NO20072997L (no) 2007-06-27
SI2371856T1 (sl) 2022-09-30
PT3130601T (pt) 2020-10-01
CN101124331B (zh) 2013-04-24
US9096656B2 (en) 2015-08-04
NO20210454A1 (no) 2007-06-27
SI2363414T1 (sl) 2022-09-30
EP3130601A1 (fr) 2017-02-15
EP2371856A2 (fr) 2011-10-05
RU2423380C2 (ru) 2011-07-10
HK1182121A1 (en) 2013-11-22
ZA200703696B (en) 2008-08-27
AU2005304622A1 (en) 2006-05-18
CN103214569B (zh) 2016-12-28
CY2019024I2 (el) 2019-11-27
HRP20070268A2 (en) 2007-09-30
BRPI0517795B1 (pt) 2020-03-31
PL2371856T3 (pl) 2022-08-22
US20060115876A1 (en) 2006-06-01
JP6559642B2 (ja) 2019-08-14
PL1824988T3 (pl) 2018-01-31
FR19C1031I1 (fr) 2019-06-28
BR122016022033B8 (pt) 2021-05-25
PT2363414T (pt) 2022-08-04
EP3130601B1 (fr) 2020-07-15
MX350293B (es) 2017-09-04
CN101124331A (zh) 2008-02-13
LT2371856T (lt) 2022-08-25
HUE033776T2 (en) 2018-01-29
NO344606B1 (no) 2020-02-10
HRP20180481A2 (hr) 2018-06-29
PH12014500352B1 (en) 2015-07-20
KR101243564B1 (ko) 2013-03-27
PT1824988T (pt) 2017-07-21
BR122016022033B1 (pt) 2021-03-02
JP6109523B2 (ja) 2017-04-05
IL182903A0 (en) 2007-08-19
CN105753968A (zh) 2016-07-13
ES2930159T3 (es) 2022-12-07
JP2017101028A (ja) 2017-06-08
EP2772500A1 (fr) 2014-09-03
KR20130036780A (ko) 2013-04-12
LUC00118I2 (fr) 2019-12-27
EP3243833A1 (fr) 2017-11-15
IL234433B (en) 2019-11-28
JP6487895B2 (ja) 2019-03-20
CY1123384T1 (el) 2021-12-31
KR20120136413A (ko) 2012-12-18
UA95225C2 (ru) 2011-07-25
DK1824988T3 (en) 2017-08-07
HUS1900026I1 (hu) 2022-04-28
DK2371856T3 (en) 2022-08-08
PH12014500352A1 (en) 2015-07-20
JP6018238B2 (ja) 2016-11-02
KR20070110260A (ko) 2007-11-16
RU2007121517A (ru) 2008-12-20
KR101904630B1 (ko) 2018-10-04
CN107082806A (zh) 2017-08-22
SI1824988T1 (sl) 2017-11-30
KR101468345B1 (ko) 2014-12-03
LT2363414T (lt) 2022-10-25
NO20200044A1 (no) 2007-06-27
CN105148287A (zh) 2015-12-16
HRP20180481B1 (hr) 2022-02-18
EP2363414A2 (fr) 2011-09-07
PL2363414T3 (pl) 2022-09-05
LUC00118I1 (fr) 2019-05-13
US20100081615A1 (en) 2010-04-01
CN105148287B (zh) 2019-07-09
HUE050542T2 (hu) 2020-12-28
PH12019501613A1 (en) 2020-09-14
ES2930143T3 (es) 2022-12-07
WO2006053299A3 (fr) 2006-08-24
HK1218718A1 (zh) 2017-03-10
CA2586379A1 (fr) 2006-05-18
US20160051633A1 (en) 2016-02-25
KR101483917B1 (ko) 2015-01-16
EP2363414B1 (fr) 2022-05-18
ES2821832T3 (es) 2021-04-27
EP3323829A1 (fr) 2018-05-23
KR20180110192A (ko) 2018-10-08
PT2371856T (pt) 2022-08-12
NL300989I1 (nl) 2019-05-22
JP2017105773A (ja) 2017-06-15
EP2371856B1 (fr) 2022-05-18
CY2019024I1 (el) 2019-11-27
HRP20070268B1 (hr) 2018-04-20
CA2586379C (fr) 2012-04-03
HUE059193T2 (hu) 2022-10-28
IL232540A (en) 2017-08-31
EP2371856A3 (fr) 2012-03-14
KR101654011B1 (ko) 2016-09-05
US9364520B2 (en) 2016-06-14

Similar Documents

Publication Publication Date Title
FR19C1031I2 (fr) Modification du facteur fviii en fonction du site
FI20030967A0 (fi) Yhteysasetusten valinta
DE502004004258D1 (de) Teleskopierbare lenkwelle
DK1667992T3 (da) Quinazolinderivater
ATE442044T1 (de) Herbizid-safener-kombination
DE502004001642D1 (de) Teleskopschiene
SE0401060L (sv) Teleskopanordning
DE502005000496D1 (de) Verstellvorrichtung
DE502004006772D1 (de) Wirkwerkzeug-Barre
DE602005002416T8 (de) Zündanordnung
FI20041334A0 (fi) Sihtilaite
DE112005002293A5 (de) Verstelleinrichtung
DE502005004692D1 (de) Massageaufsatz
ATA9992004A (de) Hydrant
ATA152004A (de) Lesepult
FR2861953B1 (fr) Crible
FI20041201A (fi) Rakennuselementti
FI20031936A0 (fi) Seula
SE0302926D0 (sv) Skärmlänsa
FIU20050035U0 (fi) Pikalukitsin
FI6236U1 (fi) Kaihdinjärjestely
SE0302274D0 (sv) Teleskopmast-kajak
FI20041108A0 (fi) Rakennuselementti
FI20070036A (fi) Valaisinlaite
UA9701S (uk) Стілець компактний